This is exciting as it suggests targeting BDNF signalling is a viable therapeutic strategy for neurologic conditions such as MS, stroke and traumatic injury where myelin damage is the prominent underlying cause of clinical dysfunction. The gene discussed is BDNF; the disease is myeloid sarcoma.